ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by DavidKingCanadaon Nov 16, 2021 12:09am

690 Views

Post# 34130207

Nasdaq listing must be Minimum $10.00 USD to make Base

If there is a 60 to 1 split then the share price once arriving on the Nasdaq must be at a minimum of $10.00 USD just to be back at even. What are the chances of that? There have been many other Companies who have done the same and either sold out or went Bankrupt.

Biogen and Eli are the Future.

PMN needs to be bought out by a bigger Company and the SP needs to be $20.00 Plus.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks